DDInter1812 DDInter1628
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentosan polysulfate
Pentosan polysulfate {u} (Compound) causes {v} (Side Effect) Haematuria
Haematuria {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Captopril
Captopril {u} (Compound) downregulates {v} (Gene) CHMP4A
CHMP4A {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Azilsartan medoxomil {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} (Compound) downregulates {v} (Gene) TRAPPC3
TRAPPC3 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Tinzaparin {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril (Compound) downregulates CHMP4A (Gene) and CHMP4A (Gene) is downregulated by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil and Azilsartan medoxomil (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) downregulates TRAPPC3 (Gene) and TRAPPC3 (Gene) is downregulated by Ruxolitinib (Compound)
Tinzaparin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)